



**HAL**  
open science

## One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes

C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, Jp. Riveline, J. Young, L. Mathivon, F. Travert, D. Morin, et al.

### ► To cite this version:

C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, et al.. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. *Diabetes, Obesity and Metabolism*, Wiley, 2016, 10.1111/dom.12606 . hal-01259859

**HAL Id: hal-01259859**

**<https://hal.sorbonne-universite.fr/hal-01259859>**

Submitted on 21 Jan 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



31 France

32 <sup>17</sup> Université Paris-Diderot Paris-7, Paris, France

33

34 \* These authors contributed equally to this work

35

36

37 Corresponding authors:

38 Corinne Vigouroux, INSERM UMR\_S938, Faculté de Médecine Pierre et Marie Curie, site Saint Antoine, 27

39 rue Chaligny, 75571, Paris Cedex 12, France.

40 Fax: +33 1 40 01 14 32, Phone: +33 1 40 01 14 84, corinne.vigouroux@inserm.fr

41

42

43 **ABSTRACT**

44 Recombinant methionyl human leptin (metreleptin) therapy was shown to improve hyperglycemia, dyslipidemia  
45 and insulin sensitivity in patients with lipodystrophic syndromes, but its effects on insulin secretion remain  
46 controversial.

47 We used dynamic intravenous clamp procedures to measure insulin secretion, adjusted to insulin sensitivity, at  
48 baseline and after one-year metreleptin therapy, in 16 consecutive patients with lipodystrophy, diabetes and  
49 leptin deficiency.

50 Patients, aged  $39.2 \pm 4$  years (mean  $\pm$  SEM), presented with familial partial lipodystrophies (n=11, 10 women)  
51 or congenital generalized lipodystrophy (n=5, 4 women). Their BMI ( $23.9 \pm 0.7$  kg/m<sup>2</sup>), HbA1c ( $8.5 \pm 0.4\%$ )  
52 and serum triglycerides ( $4.6 \pm 0.9$  mmol/l) significantly decreased within 1 month of metreleptin therapy, then  
53 remained stable. Insulin sensitivity (from hyperglycaemic or euglycemic hyperinsulinemic clamps, n = 4 and 12,  
54 respectively), insulin secretion during graded glucose infusion (n=12), and acute insulin response to intravenous  
55 glucose adjusted to insulin sensitivity (disposition index, n=12), significantly increased after 1 year of  
56 metreleptin therapy. Increase in disposition index was related to decrease in percent total and trunk body fat.

57 Metreleptin therapy improves not only insulin sensitivity, but also insulin secretion in patients with diabetes due  
58 to genetic lipodystrophies.

59

## 60 INTRODUCTION

61 Leptin deficiency, linked to reduced fat amount, is thought to importantly contribute to the metabolic  
62 complications associated with lipodystrophic syndromes, as shown by studies in mice [1,2] and humans [3,4]. In  
63 generalized forms of lipodystrophies, metreleptin therapy dramatically decreased liver and muscle lipid content,  
64 improving insulin sensitivity, hyperglycemia and dyslipidemia, partly independently of decreased caloric intake  
65 [3,4]. However, in partial forms of lipodystrophies, the effect of metreleptin on hyperglycemia has not been  
66 clearly established in patients with moderate baseline metabolic alterations [5-7]. In addition, the effect of  
67 metreleptin on insulin secretion, which remains controversial, has been previously investigated using only oral  
68 glucose tolerance tests [3,6,8-10].

69 In this study, we evaluated the effect of metreleptin on insulin sensitivity and insulin secretion using dynamic  
70 intravenous clamp procedures in 16 patients with genetic lipodystrophy syndromes, included in a compassionate  
71 therapeutic programme.

72

## 73 METHODS

74 (see also Supplementary appendix)

75

### 76 Patients

77 Twenty-two non HIV-infected patients with genetic or acquired, partial or generalized lipodystrophy, diabetes  
78 and low serum leptin (ie, fasting leptin  $\leq 6$  ng/ml), entered a compassionate programme of metreleptin therapy  
79 approved by the National French Health Agency. Among them, sixteen consecutive patients older than 16 years  
80 gave their informed consent for metabolic investigations at baseline and after one year of therapy, which were  
81 approved by the local ethics committee (Comité de Protection des Personnes, Paris-St-Louis).

82 Recombinant human methionyl-leptin (r-metHuLeptin/metreleptin, Amylin/Bristol-Myers-Squibb/AstraZeneca  
83 Pharmaceuticals, San Diego, CA), self-administered in one daily subcutaneous injection at the initial dose of  
84 0.02 mg/kg (M0) increased to 0.08 mg/kg at one month (M1), was added to the patients' regimen, stable for at  
85 least 6 weeks. Every three months, metreleptin and other medications were adapted to tolerance and  
86 effectiveness, and anthropometric parameters, lipid profile, HbA1c, renal and liver function tests were collected.  
87 The mean metreleptin daily dose at one year (M12) was 0.10 mg/kg  $\pm$  0.02 (SEM).

88

89 **Metabolic investigations** using insulin and/or glucose intravenous infusions were performed at M0 and M12.

90 The first four patients (1 to 4) were evaluated with hyperglycemic clamps, and the twelve subsequent patients (5  
91 to 16) with euglycemic hyperinsulinemic clamps and intravenous glucose tolerance test (IVGTT) followed by a  
92 graded IV-glucose infusion (glucose ramping).

93 Hyperglycemic clamps allowed the measurement of acute insulin response to an intravenous bolus of glucose  
94 (AIR), and the ratio of the glucose disposal rate to insulin concentration (M/I) at the 200 mg/dl-hyperglycemic  
95 plateau, as an estimate of insulin sensitivity.

96 Euglycemic hyperinsulinemic clamps estimated the whole-body insulin sensitivity to glucose, expressed as the  
97 insulin-stimulated glucose disposal rate (M-value), further adjusted to insulin concentrations (M/I). AIR was  
98 calculated from IVGTT. Insulin secretion rates (ISR) in response to four-step graded glucose infusions evaluated  
99 the beta-cell sensitivity to glucose.

100 The disposition index was calculated as the product of AIR by M measured during euglycemic hyperinsulinemic  
101 clamps [11].

102

### 103 **Statistical analyses**

104 A favorable effect of metreleptin on glucose control was defined as a 0.5-point decrease in HbA1c, or HbA1c  
105 stability with a decrease of more than 50% in total daily insulin or oral antidiabetic doses, or discontinuation of  
106 one antidiabetic class, between M0 and M12. Results are presented as mean  $\pm$  SEM, unless otherwise specified.  
107 See File S1 for supplemental methods and references.

108

109

## 110 **RESULTS**

### 111 **Anthropometric and metabolic markers**

112 Patients with diabetes, attributable to familial partial lipodystrophy (FPLD) linked to *LMNA* (nine women),  
113 *PPARG* (one man) or *PLIN1* mutations (one woman), or to congenital generalized lipodystrophy attributable to  
114 *AGPAT2* mutations (*CGL1*) (four women, one man) were included in the study (Table S1). They presented  
115 different forms of lipodystrophic syndromes with insulin resistance and dyslipidemia, attributable to already  
116 described causative mutations (for review, see [12]). Their age and BMI were  $39.2 \pm 4.0$  years and  $23.9 \pm 0.7$   
117  $\text{kg/m}^2$ , respectively. Their serum leptin was low ( $2.7 \pm 0.5$  ng/ml), related to fat mass ( $r^2=0.7$ ,  $p=0.003$ ). BMI,  
118 total energy intake (but not food macronutrient distribution), HbA1c, triglycerides, aspartate aminotransferase  
119 (AST) and gamma glutamyl transferase levels significantly decreased within the first month of metreleptin

120 therapy, then were not significantly modified until M12 (Table 1, Figure S1, and data not shown). After one-year  
121 metreleptin therapy, proportion of total body fat and lean masses were not significantly modified, but abdominal  
122 and percentage of truncal fat decreased or tended to decrease. Patients used a lower number of antidiabetic  
123 classes, and three among nine of them stopped insulin therapy (Table 1). One-year changes in BMI, HbA1c and  
124 triglycerides were not significantly related to baseline leptin levels.

125 Fourteen of 16 patients met the criteria for a glucose response to metreleptin. However, one of these fourteen  
126 patients cannot be formally considered as a responder since, although her glucose control was strikingly  
127 improved after one-year metreleptin whereas glitazones were stopped, her basal insulin doses were increased  
128 from 24 to 30 U/day and her metformin dose from 1g to 3g per day (patient 9, Table S2). The two non-responder  
129 patients were the only patient with a *PLIN1*-linked partial lipodystrophy, and a patient with FPLD2 with  
130 moderately elevated baseline HbA1c (patients 6 and 12, Table S2). None of them reported any difficulties  
131 regarding the compliance with the treatment. Compared to other patients with partial lipodystrophies, they had  
132 baseline values of serum leptin, percent body fat, waist circumference and duration of diabetes above the median  
133 levels. They were the only patients who did not lose, or even gained weight (+0 and +3.2 kg, respectively) over  
134 the one-year period.

### 135 **Insulin sensitivity**

136 Insulin-stimulated glucose disposal rate during euglycaemic hyperinsulinemic clamp (n=12) significantly  
137 increased during metreleptin therapy, from  $2.72 \pm 0.79$  to  $5.44 \pm 1.19$  mg/kg of fat free mass/min ( $p=0.0005$ ) for  
138 M-value and  $0.013 \pm 0.005$  to  $0.031 \pm 0.008$  mg/kg of fat free mass/min/pmol/l for M/I ( $p=0.02$ ), showing that  
139 the whole-body insulin sensitivity improved. Of note, in three patients (patients 6, 8 and 13, Table S1),  
140 euglycemia was maintained without any glucose infusion during the hyperinsulinemic clamp at baseline, while a  
141 significant glucose infusion rate was mandatory after one year-metreleptin therapy, pointing to a significant  
142 improvement in insulin sensitivity. In the four patients evaluated with the hyperglycemic clamp, M/I increased  
143 by a mean of 48% (Table S3).

### 144 **Insulin secretion**

145 Acute insulin response to intravenous glucose (AIR, n=16) did not significantly increased after one-year  
146 metreleptin therapy ( $88.9 \pm 27.5$  pmol/kg/min at M0 and  $128.8 \pm 36.4$  at M12,  $p=0.19$ ). However, insulin  
147 secretion rate (ISR) during glucose ramping was higher at every hyperglycemic step (ANOVA overall effect

148  $p < 0.0001$ ), and the disposition index (AIR x M-value), which adjusts the acute beta-cell function to insulin  
149 sensitivity [11] increased after one-year metreleptin (n=12) (Figure 1) (Table S3). The AIR x M/I index, assessed  
150 in the whole group, also significantly increased (from  $6.3 \pm 3.8$  to  $9.2 \pm 3.1$ ,  $p=0.02$ ).

151 Although one-year changes in HbA1c, triglycerides, M-value, and AIR were not significantly associated with  
152 modifications in anthropometric parameters (data not shown), disposition index variation was significantly  
153 related to changes in percent total body fat ( $r^2=0.71$ ,  $p=0.008$ ), and percent trunk fat mass ( $r^2=0.40$ ,  $p=0.05$ ).

154

### 155 **Metreleptin response in the *LMNA*-mutated subgroup of patients**

156 In patients with *LMNA* mutations (n=9), BMI, HbA1c, triglycerides and liver enzymes significantly decreased  
157 after one-year metreleptin therapy (data not shown), while M-value increased from  $2.88 \pm 1.13$  to  $6.85 \pm 1.65$   
158 mg/kg of fat free mass/min (n=7,  $p=0.02$ ). ISR increased or tended to increase at the four steps of glucose  
159 ramping, with a mean increase of 36%, and the disposition index significantly increased, from  $208.8 \pm 154.3$  to  
160  $1068 \pm 543.9$  (n=7,  $p=0.02$ ) (Figure S2 and Table S3). In this group, the decrease of HbA1c at M12 was  
161 positively correlated with the initial HbA1c level ( $r^2=0.7$ ,  $p=0.03$ ), but was not related to the initial leptinemia.

162

### 163 **DISCUSSION**

164 In patients with lipodystrophy, metreleptin therapy was shown to improve insulin sensitivity [8,13,14]. However  
165 the studies that investigated its effects on insulin secretion were done using oral glucose tolerance tests, and gave  
166 heterogeneous results [3,6,8-10]. Interestingly, leptin has been shown to have dual effects on pancreatic beta-cell  
167 function: while suppressing insulin gene expression and secretion, it also inhibits ectopic lipid storage in islet  
168 cells, thus preventing lipotoxicity in rodent models [15].

169 The present study, which used dynamic i.v. clamp techniques in 16 patients with diabetes and endogenous  
170 hypoleptinemia due to genetically-determined lipodystrophic syndromes, shows that metreleptin treatment for 1  
171 year significantly improved insulin secretion. It also confirms that it decreased HbA1c, triglycerides and liver  
172 enzymes and enhanced insulin sensitivity, with a two-fold increase in insulin-stimulated glucose disposal rate  
173 after one year, as reported [8]. Importantly, in this context of severe insulin resistance, we adjusted insulin  
174 secretion measurements for insulin sensitivity using the disposition index, based on the hyperbolic function  
175 linking acute insulin response and insulin sensitivity [11]. Improvement of this index showed that, in patients  
176 with lipodystrophy, metreleptin therapy increased beta-cell sensitivity to glucose.



177 Metreleptin-induced changes in disposition index and body fat mass and distribution were correlated, suggesting  
178 that improvement in beta-cell secretory function could result from decreased lipotoxicity. In accordance, the two  
179 non-responder patients did not lose, or even gained weight under metreleptin. Leptin could also inhibit glucagon  
180 oversecretion, which was reported in insulin-deficient mice [16] and remains to be investigated in patients with  
181 lipodystrophy under metreleptin therapy.

182 In patients with partial forms of lipodystrophies as a result of mutations in the *LMNA* gene, defects of insulin  
183 secretion have been suspected to prevent the beneficial effect of metreleptin on glucose homeostasis [5]. Our  
184 present results show that metreleptin therapy also increases insulin secretion in this subgroup of patients,  
185 affected by typical Dunnigan syndrome (FPLD2) [17] or by previously described mixed laminopathic  
186 phenotypes associating lipodystrophic syndrome and progeroid or cardiomyopathic signs [18,19]. In addition, in  
187 accordance with recent findings showing that, in patients with partial lipodystrophy, metreleptin was mainly  
188 useful if metabolic derangements were severe [7], the present study shows that effect of metreleptin on glucose  
189 control in these patients was related to the baseline level of HbA1c.

190 In conclusion, 1 year of metreleptin therapy improves beta-cell function in patients with lipodystrophy, leptin  
191 deficiency and diabetes. Improved insulin secretion, related to fat mass and distribution changes, probably  
192 contributes to the metabolic benefits of metreleptin. Further studies are required to investigate whether these  
193 effects are maintained over time and to study mechanisms by which metreleptin affects the islets. Leptin has  
194 been proposed to protect the islets by acting on several pathophysiological steps involved in beta-cell  
195 lipotoxicity and in glucagon production during diabetes [20]. These leptin-regulated pathways, which control,  
196 among others, *de novo* ceramide synthesis, could be further studied in response to metreleptin therapy.

197

198

#### 199 **ACKNOWLEDGEMENTS**

200 We thank the patients who participated in this study, the nurses from the Diabetology-Endocrinology  
201 Department of Saint-Louis hospital, Paris, France, David Savage of Addenbrooke's Hospital, Cambridge, UK for  
202 help with a genetic diagnosis, Profs Eric de Kerviler of AP-HP, Department of Radiology, Saint-Louis Hospital,  
203 Paris, France and Robert Carlier and Mr Dominique Laurent of AP-HP, Department of Radiology, Raymond-  
204 Poincaré Hospital, Paris, France for CT-scan analyses, Amylin/Bristol-Myers Squibb/AstraZeneca and in  
205 particular Dr Jean Chan and Ms Poonam Rohilla for generously providing metreleptin.

206

#### 207 **CONFLICT OF INTEREST**

208 This work was supported by funding sources from DHOS-INSERM (Translational clinical research 2010),  
209 ICAN Foundation (grant ANR-10-IAHU) and the National Program for Diabetes Research (PNRD/ARD).  
210 C.Vatier was the recipient of a PhD grant from the Conseil Régional d'Ile de France (Cardiovasculaire-Obésité-  
211 Diabète Domaine d'Intérêt Majeur). C.T received grants from the Société Francophone du Diabète.  
212 C. Vatier, JF. Gautier and C. Vigouroux designed the study, managed the metreleptin therapy, performed the  
213 metabolic clamps, collected and analysed the data and wrote the manuscript. S. Fetita, C. Tchankou and JP.  
214 Riveline performed the metabolic clamps. P. Boudou performed the biochemical tests. L. Deville and I.  
215 Madelaine managed the metreleptin delivery. J. Young, L. Mathivon, F. Travert, D. Morin, J. Cahen, F.  
216 Andreelli, Y. Reznik, E. Mongeois, MC. Vantyghem and C. Vigouroux referred the patients and collected data.  
217 O. Lascols performed the genetic analyses. All authors approved the final version of the manuscript.

218

## 219 **SUPPORTING INFORMATION**

220 Additional Supporting Information may be found in the online version of this article :

221 File S1. Supplemental methods and references.

222 Figure S1. Longitudinal effects of metreleptin therapy in the 16 patients.

223 Figure S2. Effects of metreleptin on insulin secretion in patients with *LMNA* mutations.

224 Table S1. Baseline characteristics of the 16 studied patients.

225 Table S2. Use of antidiabetic medications during metreleptin therapy.

226 Table S3. Insulin secretion and insulin sensitivity indexes before and one year after metreleptin therapy.

227

228

## 229 **REFERENCES**

230 1. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and  
231 diabetes mellitus in mice with congenital lipodystrophy. *Nature* 1999; 401: 73-76.

232

233 2. Colombo C, Cutson JJ, Yamauchi T *et al.* Transplantation of adipose tissue lacking leptin is unable to  
234 reverse the metabolic abnormalities associated with lipodystrophy. *Diabetes* 2002; 51: 2727-2733.

235

236 3. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin  
237 replacement in patients with generalized lipodystrophy. *Diabetes* 2005; 54: 1994-2002.

238

239 4. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of  
240 human lipodystrophy. *Diabetologia* 2010; 53: 27-35.

241

242 5. Simha V, Subramanyam L, Szczepaniak L *et al.* Comparison of efficacy and safety of leptin  
243 replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of  
244 the Dunnigan variety. *J Clin Endocrinol Metab* 2012; 97: 785-792.

245

- 246 6. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in  
247 patients with Dunnigan-type familial partial lipodystrophy. *Metabolism* 2007; 56: 508-516.  
248
- 249 7. Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of  
250 baseline characteristics and response to metreleptin. *J Clin Endocrinol Metab* 2015; 100: 1802-1810.  
251
- 252 8. Ebihara K, Kusakabe T, Hirata M *et al.* Efficacy and safety of leptin-replacement therapy and possible  
253 mechanisms of leptin actions in patients with generalized lipodystrophy. *J Clin Endocrinol Metab* 2007; 92: 532-  
254 541.  
255
- 256 9. Guettier JM, Park JY, Cochran EK *et al.* Leptin therapy for partial lipodystrophy linked to a PPAR-  
257 gamma mutation. *Clin Endocrinol (Oxf)* 2008; 68: 547-554.  
258
- 259 10. Muniyappa R, Brown RJ, Mari A *et al.* Effects of Leptin Replacement Therapy on Pancreatic beta-Cell  
260 Function in Patients With Lipodystrophy. *Diabetes Care* 2014; 37: 1101-1107.  
261
- 262 11. Kahn SE, Prigeon RL, McCulloch DK *et al.* Quantification of the relationship between insulin  
263 sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes* 1993; 42:  
264 1663-1672.  
265
- 266 12. Vatier C, Bidault G, Briand N *et al.* What the genetics of lipodystrophy can teach us about insulin  
267 resistance and diabetes. *Curr Diab Rep* 2013; 13: 757-767.  
268
- 269 13. Oral EA, Simha V, Ruiz E *et al.* Leptin-replacement therapy for lipodystrophy. *N Engl J Med* 2002;  
270 346: 570-578.  
271
- 272 14. Beltrand J, Beregszaszi M, Chevenne D *et al.* Metabolic correction induced by leptin replacement  
273 treatment in young children with Berardinelli-Seip congenital lipodystrophy. *Pediatrics* 2007; 120: e291-e296.  
274
- 275 15. Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic beta-cell  
276 function. *Metabolism* 2011; 60: 1664-1672.  
277
- 278 16. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents  
279 thrive without insulin. *Proc Natl Acad Sci U S A* 2008; 105: 14070-14075.  
280
- 281 17. Vigouroux C, Magré J, Vantyghem MC *et al.* Lamin A/C gene: sex-determined expression of mutations  
282 in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired  
283 generalized lipodystrophy. *Diabetes* 2000; 49 : 1958-1962.  
284
- 285 18. Caron M, Auclair M, Donadille B *et al.* Human lipodystrophies linked to mutations in A-type lamins  
286 and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and  
287 premature cellular senescence. *Cell Death Differ* 2007; 14: 1759-1767.  
288
- 289 19. Garg A, Speckman RA, Bowcock AM. Multisystem dystrophy syndrome due to novel missense  
290 mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. *Am J Med* 2002;  
291 112: 549-55.  
292
- 293 20. Unger RH, Roth MG. A new biology of diabetes revealed by leptin. *Cell Metab* 2015; 21: 15-20.  
294

## FIGURE 1 LEGEND

### Effect of metreleptin therapy on insulin secretion

A. Insulin secretion rates (ISR) during graded glucose infusion were calculated for each of the four glucose infusion steps (of 4, 8, 10 and 12 mg/ kg of body weight of glucose per min) and plotted against the corresponding mean glucose concentration, in patients 5 to 16. Mean values obtained at baseline are represented as empty circles, and those obtained at one year-metreleptin therapy as filled triangles. Whiskers represent SEM.

\*  $p < 0.05$  versus M0

B. Disposition index, indicating the insulin secretion capacity relative to insulin sensitivity, was calculated in the same patients as the product of M value measured during the euglycemic hyperinsulinemic clamp by AIR. Rectangles represent 25<sup>th</sup> and 75<sup>th</sup> percentile values, with the median values depicted in-between. Whiskers represent the lowest datum still within 1.5 IQR of the lower quartile, and the highest datum still within 1.5 IQR of the upper quartile (Tukey boxplot).

M0: baseline, M12: after 12 months of metreleptin therapy; \*  $p < 0.05$  versus M0



**Table 1:** Metabolic markers at baseline and after one year of metreleptin treatment in the sixteen studied patients

<b>Variable</b>	<b>Baseline</b>	<b>12 month-metreleptin</b>	<b>p</b>
<b><u>Body weight and body composition</u></b>			
BMI (kg/m <sup>2</sup> )	23.9 (0.7)	22.6 (0.8)	<b>0.003</b>
Waist circumference (cm)	81.8 (7.0)	77.5 (8.5)	<b>0.004</b>
Abdominal total adipose tissue area (cm <sup>2</sup> , CT-scan)	195.9 (29.3)	144.0 (24.4)	<b>0.03</b>
Abdominal visceral adipose tissue area (cm <sup>2</sup> , CT-scan)	122.2 (17.7)	94.6 (15.7)	<b>0.0005</b>
Abdominal subcutaneous adipose tissue area (cm <sup>2</sup> , CT-scan)	73.7 (13.6)	49.4 (11.8)	<b>0.006</b>
Fat mass (% of total body mass, DEXA)	15.4 (1.6)	14.7 (1.5)	0.6
Trunk fat mass (% of total body mass, DEXA)	18.7 (2.4)	17.8 (2.4)	0.08
Lean mass (% of total body mass, DEXA)	82.1 (1.7)	85.5 (2.5)	0.8
<b><u>Energy intake</u></b>			
Total food intake (Kcal/day)	1970 (108.1)	1717 (112.8)	<b>0.03</b>
<b><u>Metabolic, renal and liver parameters</u></b>			
Systolic blood pressure (mmHg)	130.1 (3.4)	125.1 (3.0)	0.23
HbA1c (%)	8.5 (0.4)	7.5 (0.3)	<b>0.005</b>
Fasting Glucose (mmol/l)	7.5 (0.5)	7.0 (0.8)	0.5
Fasting Insulin (pmol/l)	259.2 (81.2)	380.9 (125.8)	0.7
LDL-cholesterol (mmol/l)	2.5 (0.3)	2.0 (0.02)	0.14
HDL-cholesterol (mmol/l)	0.7 (0.04)	0.8 (0.04)	0.24
Triglycerides (mmol/l)	4.6 (0.9)	3.4 (0.9)	<b>0.03</b>
Aspartate aminotransferase (AST) (IU/l)	47.8 (8.5)	32.4 (2.9)	<b>0.03</b>
Alanine aminotransferase (ALT) (IU/l)	70.9 (17.2)	49.4 (6.9)	0.3
Gamma glutamyl transferase (GGT) (IU/l)	84.9 (21.7)	57.6 (19.9)	<b>0.05</b>
Creatinine (μmol/l)	62.4 (4.8)	66.7 (4.9)	<b>0.03</b>
Albumin excretion rate (mg/l)	297.5 (166.5)	83.4 (55.9)	0.12
<b><u>Therapy</u></b>			
Antidiabetic medication classes per patient	2.2 (0.28)	1.6 (0.26)	<b>0.008</b>
Insulin users (n)	9/16	6/16	
Lipid-lowering medications per patient	Fibrate 9/16 Statin 6/16	Fibrate 9/16 Statin 4/16	

Values are expressed as mean (SEM). p values are depicted in bold when considered significant (p < 0.05).

Total, visceral and subcutaneous abdominal adipose tissue areas were evaluated from 1cm-reconstructed CT-scan slices at the L4 level. DEXA: dual energy x-ray absorptiometry

**Figure 1: Effect of metreleptin therapy on insulin secretion**



▲ After one-year metreleptin therapy (M12)

○ Baseline (M0)

## **Additional Supporting Information**

### **File S1. Supplemental methods and references**

#### **Methods**

##### **Biochemical analyses**

HbA1c was measured using high performance liquid chromatography and plasma insulin using a immunoradiometric assay (BI-INSULIN IRMA, Cis Bio-International, Gif-Sur-Yvette, France).

The values of LDL-cholesterol were determined from total cholesterol, triglycerides and HDL-cholesterol levels using the Friedewald formula ( $\text{LDL-cholesterol} = \text{total cholesterol} - \text{HDL-cholesterol} - \text{triglycerides} (\text{mg/dl}) / 5$ ), when triglycerides levels were below 400 mg/dl (n=9 patients).

##### **Evaluation of body composition**

Total fat and lean masses, and body fat segmental distribution, were measured by dual energy x-ray absorptiometry (DEXA), and abdominal subcutaneous and visceral adipose tissue surfaces (SAT and VAT) were calculated from 1 cm-reconstructed CT-scan slices at the L4 level as previously described [1].

**Caloric and macronutrient intakes** were evaluated by three-day food records performed at M0 and M12.

##### **Metabolic investigations**

Metabolic investigations were performed after a 12h-overnight fast at M0 and M12. When fasting glycemia was above 7 mmol/l, a 2h-insulin infusion was performed before the investigations. Intravenous glucose tolerance tests (IVGTT, n=16), hyperglycemic and euglycemic hyperinsulinemic clamps (n= 4 and 12, respectively), and graded glucose infusion tests (glucose ramping, n=12) were performed as previously described [2-6].

##### ***Acute insulin response to an intravenous bolus of glucose (AIR) (n=16 patients)***

In all patients, a solution of 20% glucose of  $[\text{weight (kg)} \times (200 - \text{fasting glycemia (mg/dl)}) \times 1.5] / 200$  ml was given within 30 seconds intravenously and measurements of plasma glucose and insulin were performed at -5, 0, 2, 4, 6, 8 and 10 min. AIR was defined as the incremental area under the curve of plasma insulin concentration above baseline between 2 and 10 min after intravenous glucose administration according to the trapezoid method. Baseline insulin (InsB) was the mean insulin level between -5 and 0min  $[(\text{Ins}_{-5\text{min}} + \text{Ins}_{0\text{min}}) / 2]$ . AIR=

$[(IT_{0min} + IT_{2min})/2 - IT_{0min}] + [(IT_{2min} + IT_{4min})/2 - IT_{0min}] + [(IT_{4min} + IT_{6min})/2 - IT_{0min}] +$   
 $[(IT_{6min} +$   
 $IT_{8min})/2 - IT_{0min}] + [(IT_{8min} + IT_{10min})/2 - IT_{0min}]$  and expressed as pmol/kg/min.

#### ***Hyperglycemic clamp (patients 1 to 4)***

Following the intravenous bolus of glucose for the AIR determination, we maintained plasma glucose at 200 mg/dl for 180 min by infusing 20% glucose at varying rates according to blood glucose measurements reformed at 5min-intervals. Blood samples were collected at 160<sup>th</sup>, 170<sup>th</sup> and 180<sup>th</sup> min for the measurement of plasma insulin and C peptide concentrations. We calculated the glucose disposal rate from the glucose infusion rate during the last 20 min of the hyperglycemic plateau after accounting for inter-individual differences in glucose space [3] (in mg/kg body fat-free mass/min). Glucose space correction was calculated as  $(G_2 - G_1) \times 0.095$  with  $G_2$  and  $G_1$  being the glucose concentrations in mg/dl at the end and at the beginning of each 5-min period during the last 20 min of the clamp. The ratio of the glucose disposal rate to insulin concentration at the 200 mg/dl-hyperglycemic plateau (M/I) was used as an estimate of insulin sensitivity.

#### ***Euglycemic hyperinsulinemic clamp (patients 5 to 16)***

The insulin-stimulated glucose disposal rate (M-value) was measured during a 100 min-step of 80 mU/m<sup>2</sup>/min insulin infusion, while blood glucose was clamped at 100 mg/dl using variable infusion of 20% glucose. Blood samples were collected before the clamp and every 10 min during the last 20 min, for the measurement of plasma glucose and insulin. The M-value was calculated according to DeFronzo et al. [3], after accounting for inter-individual differences in glucose space, and was expressed in mg/kg of fat-free mass/min, using the formula described above. We also calculated the M/I ratio, which adjusted the M-value to the mean insulin concentration during the last 20 min of the test.

#### ***Glucose ramping (graded glucose infusion test) (patients 5 to 16)***

This test consisted of four consecutive 40-min intravenous infusion of 4, 8, 10 and 12 mg/kg/min of glucose as previously described [2,4]. Blood samples were collected every 10 minutes during the whole procedure (200 min). The insulin secretion rates (ISR), which evaluate the beta-cell sensitivity to glucose, were assessed from the changes in C-peptide concentrations and the pre-hepatic insulin secretion rate for each of the four glucose infusion steps. ISR was derived by deconvolution, assuming a two-compartmental model of C-peptide clearance kinetic, using the ISEC software version 3.4a designed by Hovorka R et al (see [5] for more details). Mean ISR for each glucose infusion step was adjusted to fat-free mass and plotted against the



corresponding mean glucose concentration, thereby establishing a dose-response relationship between plasma glucose and insulin secretion rate for each patient.

The *disposition index (patients 5 to 16)* was calculated as the product of AIR by M-value measured during euglycemic hyperinsulinemic clamps [6].

### **Statistical analyses**

Statistical analyses were performed using GraphPad PRISM (GraphPad Software, Inc, CA, USA) and Statview (SAS Institute Inc., CA, Austria) statistical softwares. We used the Fisher exact test to compare categorical variables and the non-parametric Mann Whitney U test. Analysis of variance (ANOVA) and Wilcoxon rank-sum test for quantitative variables were performed for comparisons over time. The relationship between ISR and glucose levels during glucose ramp was analyzed using mixed model analysis of covariance. Correlations of different measures of glucose metabolism with body composition or age were evaluated using Spearman's rank correlation test or linear regression analysis. *P* values <0.05 were considered significant.

### **References**

1. Boufassa F, Goujard C, Viard JP *et al.* Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. *Antivir Ther* 2012; 17: 91-100.
2. Gautier JF, Wilson C, Weyer C *et al.* Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. *Diabetes* 2001; 50: 1828-1833.
3. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 1979; 237: E214-E223.
4. Sobngwi E, Boudou P, Mauvais-Jarvis F *et al.* Effect of a diabetic environment in utero on predisposition to type 2 diabetes. *Lancet* 2003; 361: 1861-1865.
5. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. *Comput Methods Programs Biomed* 1996; 50: 253-264.
6. Kahn SE, Prigeon RL, McCulloch DK *et al.* Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes* 1993; 42: 1663-1672.

**Table S1:** Baseline characteristics of the sixteen studied patients


Patients	Age (years)	Sex (M/F)	Disease (gene mutation)	BMI (kg/m <sup>2</sup> )	Total body fat mass (% , DEXA)	Serum leptin (ng/ml)	Known duration of diabetes (years)
1	60	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	22.8	21.8	0.6	23
2	37	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	25.7	18.1	1.4	16
3	24	F	CGL1 (HMZ <i>AGPAT2</i> p.L165-Q196del)	26.8	8.8	0.1	6
4	17	F	CGL1 (HMZ <i>AGPAT2</i> p.Q196fsX228)	20.3	11.2	1.7	3
5	52	F	CGL1 (HMZ <i>AGPAT2</i> p.K216X)	21.5	8.4	0.1	38
6	51	F	FPLD4 (HTZ <i>PLIN1</i> p.V398GfsX166)	26.0	22.2	5.0	30
7	50	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	24.5	21.3	4.1	6
8	41	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	23.0	13.4	3.4	22
9	19	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	25.0	22.6	5.6	3
10	50	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	25.2	13.8	3.6	1
11	16	F	Progeroid laminopathy (HTZ <i>LMNA</i> p.D47Y)	17.4	7.2	1.1	2
12	36	F	FPLD2 (HTZ <i>LMNA</i> p.R482W)	24.5	24.2	3.9	22
13	45	M	FPLD3 (HTZ <i>PPARG</i> p.L339X)	29.0	22.6	4.0	22
14	29	F	CGL1 (HMZ <i>AGPAT2</i> p.Q196fsX228)	24.1	10.1	2.2	29
15	70	M	CGL1 (HMZ <i>AGPAT2</i> p.E172K)	21.4	4.2	0.34	42
16	31	F	Mixed laminopathy (HTZ <i>LMNA</i> p.R28W)	24.8	16.9	6	20
Mean ± SEM	39.2 ± 4.0			23.9 ± 0.7	15.4 ± 1.6	2.7 ± 0.5	17.8 ± 3.3

FPLD: Familial Partial Lipodystrophy; CGL: Congenital Generalized Lipodystrophy; AGL: Acquired Generalized Lipodystrophy; HTZ: heterozygous; HMZ: homozygous; DEXA: dual energy x-ray absorptiometry

**Table S2:** Use of antidiabetic medications during metreleptin therapy

Patients	Type of lipodystrophy	Antidiabetic treatment (except insulin)		Insulin doses (U/d)		HbA1c	
		M0	M12	M0	M12	M0	M12
1	FPLD2	Metformin 3 g/d Pioglitazone 45 mg/d Glimepiride 4 mg/d	Metformin 3 g/d Glimepiride 4 mg/d	0	0	7.7	6.9
2	FPLD2	Metformin 1.7 g/d Pioglitazone 30 mg/d Glibenclamide 2 mg/d	Metformin 1.7 g/d Glibenclamide 1 mg/d	0	0	7.7	6.9
3	CGL1	Metformin 3g/d	Metformin 3g/d	0	0	8.7	6
4	CGL1	None	None	61	0	7.6	6.4
5	CGL1	None	None	60	0	8.1	7.1
6	FPLD4	Metformin 3 g/d	Metformin 3 g/d	254	564	9	10.2
7	FPLD2	Metformin 2 g/d	Metformin 2 g/d	0	0	8.5	7.4
8	FPLD2	Metformin 3 g/d	Metformin 3g/d	140	40	6.9	6.9
9	FPLD2	Metformin 1 g/d Pioglitazone 45 mg/d Gliclazide 120 mg/d Liraglutide 1.8 mg/d	Metformin 3 g/d Gliclazide 120 mg/d Liraglutide 1.8 mg/d	24	30	12.1	9.2
10	FPLD2	Metformin 1.7 g/d	Metformin 1.7 g/d	0	0	7.1	6.2
11	Progeroid laminopathy	Metformin 1.4 g/d Pioglitazone 30 mg/d	Metformin 1.4 g/d	202	0	10.4	9
12	FPLD2	Metformin 0.7 g/d Vildagliptin 100 mg/d	Metformin 0.7 g/d Vildagliptin 100 mg/d	0	0	7.1	7.2
13	FPLD3	Metformin 3 g/d Glibenclamide 4 mg/d Liraglutide 1.8 mg/d	Metformin 3 g/d Glibenclamide 4 mg/d Liraglutide 1.8 mg/d	0	0	10.8	9.9
14	CGL1	Metformin 2.55 g/d	None	80	68	8.7	8
15	CGL1	Metformin 3 g/d	None	180	180	8.3	6.8
16	Mixed laminopathy	Metformin 3 g/d Glibenclamide 4 mg/d	Metformin 2.1 g/d	272	220	7.6	6

**Figure S1 : Longitudinal effects of metreleptin therapy in the 16 patients**




**D.**

Variable	Baseline	1 month-metreleptin therapy (M1)	p M1 versus baseline	12 month-metreleptin therapy (M12)	p M12 versus baseline	p M1 versus M12
BMI (kg/m <sup>2</sup> )	23.9 (0.7)	22.9 (0.7)	<b>0.0009</b>	22.6 (0.8)	<b>0.003</b>	0.06
HbA1c (%)	8.5 (0.4)	7.6 (0.3)	<b>0.0005</b>	7.5 (0.3)	<b>0.005</b>	0.57
Triglycerides (mmol/l)	4.6 (0.9)	3.1 (0.5)	<b>0.004</b>	3.4 (0.9)	<b>0.03</b>	0.93
Total food intake (Kcal/day)	1970 (108.1)	1880 (159.4)	<b>0.03</b>	1717 (112.8)	<b>0.03</b>	0.69
Aspartate aminotransferase	47.8 (8.5)	27.3 (1.5)	<b>0.003</b>	32.4 (2.9)	<b>0.03</b>	0.06
Gamma glutamyl transferase	84.9 (21.7)	45.5 (9.2)	<b>0.03</b>	57.6 (19.9)	<b>0.05</b>	0.45

Figure S2

Effect of metreleptin on insulin secretion in patients with *LMNA* mutations


**A. Insulin secretion rates during graded glucose infusion**



○ Baseline (M0)

▲ After one-year metreleptin therapy (M12)

**B. Integrative marker: disposition index**



**Table S3****Insulin secretion and insulin sensitivity indexes before and one year after metreleptin therapy****3 A. intravenous glucose tolerance test (IVGTT) followed by hyperglycemic clamps**

Patients	Type of lipodystrophy	Acute Insulin Response (pmol/kg/min)		M-value/Insulinemia (mg/kg of fat free mass/min/pmol/l)		AIR x M/I	
		M0	M12	M0	M12	M0	M12
1	FPLD2	182.7	208	0.033	0.058	6.03	12.06
2	FPLD2	31.3	50	0.184	0.125	5.76	6.25
3	CGL1	80.1	532	0.035	0.061	2.80	32.45
4	CGL1	99	81.5	0.037	0.065	3.66	6.43

**3 B. Euglycemic hyperinsulinemic clamps and intravenous glucose tolerance test (IVGTT) followed by a glucose ramping**

Patients	Type of lipodystrophy	Acute Insulin Response (pmol/kg/min)		M-value (mg/kg of fat free mass/min)		Disposition index (AIR x M-value)	
		M0	M12	M0	M12	M0	M12
5	CGL1	5	79.6	6.43	8.28	32.2	658.5
6	FPLD4	10	56.2	0	0.33	0	18.5
7	FPLD2	25.2	29.6	6.96	10.05	175.4	297.5
8	FPLD2	124.2	37.5	0	2.74	0	102.7
9	FPLD2	25.9	46.3	1.82	9.60	47.1	444.1
10	FPLD2	43	385.6	2.12	9.30	91.1	3586.0
11	Progeroid laminopathy	426.4	27.8	0.05	2.05	21.8	57.0
12	FPLD2	155.8	222	7.21	12.03	1123.4	2670.7
13	FPLD3	9.7	15.7	0	0.77	0	12.1
14	CGL1	179.6	97	3.01	3.96	540.6	384.1
15	CGL1	24.2	44.1	3.02	3.96	73.1	174.6
16	Mixed laminopathy	1.0	148	1.99	2.15	1.99	318.2

## Supplementary Figure legends

### Figure S1

#### Longitudinal effects of metreleptin therapy in the 16 patients

Values of BMI (A), HbA1c (B) and serum triglycerides (C) are depicted as rectangles which represent 25<sup>th</sup> and 75<sup>th</sup> percentile values, with the median values depicted in-between. Whiskers represent the lowest datum still within 1.5 IQR of the lower quartile, and the highest datum still within 1.5 IQR of the upper quartile (Tukey boxplot). M: months after the onset of metreleptin therapy. \*:  $p < 0.05$  versus M0

Data expressed as mean (SEM) with statistical analyses are presented in (D).

### Figure S2

#### Effect of metreleptin on insulin secretion in patients with *LMNA* mutations

A. Insulin secretion rates (ISR) during graded glucose infusion were derived by deconvolution as described, for each of the four glucose infusion steps (of 4, 8, 10 and 12 mg per kg of body weight of glucose per min), in 7 patients (patients 7 to 12 and patient 16). ISR expressed in pmol/kg of fat-free mass/min, were plotted against the corresponding mean glucose concentration. Mean values obtained at baseline are represented as empty circles, and those obtained at one year-metreleptin therapy as filled triangles. Whiskers represent SEM.

B. Disposition index, indicating the insulin secretion capacity relative to insulin sensitivity, was calculated in the same patients as the product of M value measured during the euglycemic hyperinsulinemic clamp by AIR. Rectangles represent 25<sup>th</sup> and 75<sup>th</sup> percentile values, with the median values depicted in-between. Whiskers represent the lowest datum still within 1.5 IQR of the lower quartile, and the highest datum still within 1.5 IQR of the upper quartile (Tukey boxplot).

M0: baseline, M12: after 12 months of metreleptin therapy; \*  $p < 0.05$  versus M0